The Parkinson's Progression Markers Initiative (PPMI)
is a landmark study launched in 2010 to find biomarkers -- disease indicators that are critical missing links in the search for better Parkinson's disease (PD) treatments.
At PPMI's 33 clinical sites in 11 countries, nearly 1,000 participants -- everyday patients and their loved ones -- are contributing invaluable data and biosamples into the most robust Parkinson's database and specimen bank ever created. These resources are paired with a simple online system allowing researchers to access study data and samples for complementary PD research in their own labs across the globe. Because PPMI is an observational study, research volunteers do not take any experimental drug or placebo, but agree to contribute data and samples for up to five years. A $60-million study, PPMI is sponsored by The Michael J. Fox Foundation and funded by the Foundation in partnership with 18 biotech and pharmaceutical companies.
Meet the patients, friends & families making PPMI possible
Already enrolled in PPMI?
For Researchers: Access PPMI data & more.